Stomach Cancer – is also known as Gastric Cancer
Bacteria causes 95% of all Stomach Cancers
Stomach cancer, also known as gastric cancer, is the accumulation of an abnormal (malignant, cancerous) group of cells that form a tumour in any part of the stomach – in most cases, it refers to cancer that starts off in the mucus-producing cells on the lining of the inside of the stomach (technically known as adenocarcinoma).
About 90% to 95% of cancers of the stomach are adenocarcinomas.
According to NCI’s Surveillance, Epidemiology, and End Results (SEER) Program, an estimated 22,220 people in the United States will be newly diagnosed with stomach cancer and 10,990 people will die of this cancer during 2014. Stomach cancer is the second most common cause of cancer-related deaths in the world, killing approximately 738,000 people in 2008 (1). Stomach cancer is less common in the United States and other Western countries than in countries in Asia and South America.
Stomach cancers tend to develop slowly over many years. Before a true cancer develops, pre-cancerous changes often occur in the inner lining (mucosa) of the stomach. These early changes rarely cause symptoms and therefore often go undetected.
Two thirds of the Worlds population carry this bacterium in their stomach and gut. In most people this does not cause a problem, but there is always the risk that the bacterium may turn from harmless to dangerous.
From 2001 to 2005 a number of studies by Hideki Masuda, Ph.D were carried out that showed that Wasabia japonica ITC’s killed this bacterium, even if it had got into the lining of the stomach where conventional drugs or antibiotics can’t reach it.
Epidemiologic studies have shown that individuals infected with H. pylori have an increased risk of stomach cancer (2-8). A 2001 combined analysis of 12 case–control studies of H. pylori and stomach cancer estimated that the risk of stomach cancer was nearly six times higher for H. pylori-infected people than for uninfected people (4).
Additional evidence for an association between H. pylori infection and the risk of stomach cancer comes from prospective cohort studies such as the Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study in Finland (9). Comparing subjects who developed stomach cancer with cancer-free control subjects, the researchers found that H. pylori-infected individuals had a nearly eightfold increased risk for stomach cancer (10).
Can treatment to eradicate H. pylori infection reduce stomach cancer rates?
Long-term follow-up of data from a randomized clinical trial carried out in Shandong, China — an area where rates of stomach cancer are very high — found that short-term treatment with antibiotics to eradicate H. pylori reduced the incidence of stomach cancer. During a nearly 15-year period after treatment, stomach cancer incidence was reduced by almost 40 percent (11). When the results of this trial were pooled with those of several smaller trials examining the effects on stomach cancer incidence of antibacterial treatment to eradicate H. pylori, a similar reduction was seen (11).
The use of Wasabia japonica as an alternative to antibiotics was not considered during these studies, but the results found in the 2001 – 2005 studies show that Wasabia japonica would be a less hazardous treatment to kill the H. pylori bacterium.
It would also reduce the risk of getting Stomach Cancer by killing the main cause.
Who should seek diagnosis and treatment of an H. pylori infection?
According to the Centers for Disease Control and Prevention (CDC), people who have active stomach or duodenal ulcers or a documented history of ulcers should be tested for H. pylori, and, if they are infected, should be treated. Testing for and treating H. pylori infection is also recommended after removal of early stomach cancer and for low-grade stomach MALT lymphoma.
Prevention is better than the cure.
Taking 3 capsules of Wasabia japonica a day will not only kill the cause of Stomach or Gastric Cancer, but also most of the other cancers that continually invade our bodies. It should also be mentioned that H. pylori causes Stomach or Duodenal or Peptic Ulcers so the removal of the bacterium from your body is of great benefit in the prevention of future or even existing stomach problems.
1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010; 127(12):2893–2917. [PubMed Abstract]
2. Atherton JC. The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Annual Review of Pathology 2006; 1:63–96. [PubMed Abstract]
3. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clinical Microbiology Reviews 2006; 19(3):449–490. [PubMed Abstract]
4. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: A combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49(3):347–353. [PubMed Abstract]
5. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. New England Journal of Medicine 1991; 325(16):1127–1131. [PubMed Abstract]
6. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and. Gastroenterology 1998; 114(6):1169–1179. [PubMed Abstract]
7. Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: A meta-analysis. American Journal of Gastroenterology 1999; 94(9):2373–2379. [PubMed Abstract]
8. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. New England Journal of Medicine 2001; 345(11):784–789. [PubMed Abstract]
9. The alpha-tocopherol, beta-carotene lung cancer prevention study: Design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. Annals of Epidemiology 1994; 4(1):1–10. [PubMed Abstract]
10.Kamangar F, Dawsey SM, Blaser MJ, et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. Journal of the National Cancer Institute 2006; 98(20):1445–1452. [PubMed Abstract]
11. Ma JL, Zhang L, Brown LM, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute 2012; 104(6):488-492. [PubMed Abstract]